Vivani Medical, Inc. is a clinical-stage biopharmaceutical company that specializes in developing innovative implantable medical devices. The firm aims to address chronic diseases for which current treatments are insufficient or lacking. Its key initiatives include a portfolio of miniature drug implants, designed to ensure consistent and stable therapeutic drug delivery, as well as advanced implantable visual prostheses intended to provide meaningful artificial vision to blind individuals. Vivani Medical is headquartered in Emeryville, California.
Price Overview
Last updated: Jul 8, 2026 11:32pm (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -0.43
Total Equity: $15.73M
Shares: 62,389,000
Total Debt: $17.06M
Cash: $16.23M
EBITDA: -$26.19M
Total Debt: $17.06M
Cash: $16.23M
Revenue: $0.00
Shares: 62,389,000
Revenue: $0.00
Revenue: $0.00
Revenue: $0.00
Total Equity: $15.73M
Tax Rate: 0.0%
Equity: $15.73M
Total Debt: $17.06M
Cash: $16.23M
Current Liabilities: $6.60M
Long-Term Debt: $17.06M
Total Debt: $17.06M
Total Equity: $15.73M
Shares: 62,389,000
Shares: 62,389,000
CapEx: -$1.17M
Shares: 62,389,000
Stock Price: $1.60
Net Income: -$26.61M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jul 8, 2026 10:23pm (1h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $357,000 | $0 | $424,000 |
| Gross Profit | $0 | $0 | $-357,000 | $0 | $-424,000 |
| Operating Expenses | $13.3M | $21.2M | $26.6M | $24.7M | $27.1M |
| Operating Income | -$13.3M | -$21.2M | -$27.0M | -$24.7M | -$27.6M |
| Net Income | -$12.8M | -$13.9M | -$25.7M | -$23.5M | -$26.6M |
| EBITDA | -$12.4M | -$19.2M | -$25.3M | -$23.1M | -$26.2M |
| EPS | $-0.33 | $-0.17 | $-0.50 | $-0.43 | $-0.43 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jul 8, 2026 10:23pm (1h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $2.2M | $45.1M | $20.7M | $18.4M | $16.2M |
| Total Current Assets | $2.5M | $47.5M | $23.1M | $20.4M | $17.9M |
| Total Assets | $5.5M | $51.1M | $45.8M | $41.6M | $39.4M |
| Current Liabilities | $2.1M | $6.8M | $5.7M | $6.0M | $6.6M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $17.1M |
| Total Liabilities | $3.0M | $6.8M | $25.0M | $24.0M | $23.7M |
| Total Equity | $2.5M | $44.3M | $20.8M | $17.6M | $15.7M |
| Retained Earnings | -$58.9M | -$72.8M | -$98.4M | -$121.9M | -$148.5M |
Cash Flow (Annual)
Last updated: Jul 8, 2026 10:23pm (1h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$11.0M | -$18.8M | -$23.7M | -$20.8M | -$24.3M |
| Capital Expenditure | $-572,000 | $-338,000 | $-887,000 | $-556,000 | -$1.2M |
| Free Cash Flow | -$11.5M | -$19.1M | -$24.6M | -$21.3M | -$25.5M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $-28,000 |
| Net Change in Cash | $97,000 | $44.3M | -$24.5M | -$2.3M | -$2.1M |
Analyst Estimates (Annual)
Last updated: Jul 8, 2026 10:23pm (1h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue | $0 | $0 |
$18.0M $18.0M – $18.0M
|
$51.3M $51.3M – $51.3M
|
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
-$33.9M -$40.6M – -$25.0M
|
-$26.8M -$26.8M – -$26.8M
|
-$28.7M -$28.7M – -$28.7M
|
-$23.7M -$23.7M – -$23.7M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jul 8, 2026 10:23pm (1h ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | — | — | +100.0% | — |
| Operating Income Growth | -59.4% | -26.9% | +8.5% | -11.7% |
| Net Income Growth | -8.7% | -84.7% | +8.4% | -13.3% |
| EBITDA Growth | -54.2% | -32.0% | +8.7% | -13.4% |
Insider Trading (Recent)
Last updated: Jul 8, 2026 10:23pm (1h ago)All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-24 | Moretti August J | A-Award | 36,000.00 | $1.22 | $43,920 |
| 2026-06-24 | Moretti August J | 0.00 | $0.00 | $0 | |
| 2026-06-24 | Williams Gregg | A-Award | 36,516.00 | $1.22 | $44,550 |
| 2026-06-24 | Popoff Alexandra L. | A-Award | 36,516.00 | $1.22 | $44,550 |
| 2026-06-24 | BRADBURY DANIEL | A-Award | 36,516.00 | $1.22 | $44,550 |
| 2026-06-24 | Mendelsohn Aaron | A-Award | 36,516.00 | $1.22 | $44,550 |
| 2026-06-15 | Williams Gregg | P-Purchase | 1,587,301.00 | $1.26 | $2.0M |
| 2026-05-15 | Williams Gregg | P-Purchase | 1,587,301.00 | $1.26 | $2.0M |
| 2026-04-15 | Williams Gregg | P-Purchase | 1,587,301.00 | $1.26 | $2.0M |
| 2026-03-15 | Williams Gregg | P-Purchase | 264,551.00 | $1.26 | $333,334 |
| 2026-03-15 | Williams Gregg | P-Purchase | 1,310,680.00 | $1.03 | $1.4M |
| 2026-02-15 | Williams Gregg | P-Purchase | 264,551.00 | $1.26 | $333,334 |
| 2026-02-15 | Williams Gregg | P-Purchase | 1,601,941.00 | $1.03 | $1.6M |
| 2026-01-27 | Williams Gregg | P-Purchase | 1,351,351.00 | $1.48 | $2.0M |
| 2026-01-15 | Williams Gregg | P-Purchase | 264,551.00 | $1.26 | $333,334 |
| 2026-01-15 | Williams Gregg | P-Purchase | 1,473,214.00 | $1.12 | $1.6M |
| 2026-01-01 | BRADBURY DANIEL | A-Award | 47,212.00 | $1.23 | $58,071 |
| 2026-01-01 | Williams Gregg | A-Award | 72,392.00 | $1.23 | $89,042 |
| 2025-12-29 | Mendelsohn Aaron | P-Purchase | 20,000.00 | $1.23 | $24,600 |
| 2024-07-08 | Mendelsohn Aaron | G-Gift | 20,000.00 | $0.00 | $0 |
Narrative Economics
market-narrative step).